Key facts
- It has raised $12.7M; the latest was Later Stage VC ($30K) in Apr 2026.
- Notable investors include Tech Incubator Program for Startup, Korea Investment Partners, Samsung Venture Investment, Smilegate Investment, STIC Ventures — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Adel
- ·The full record, as it builds
Funding rounds
No funding rounds for Adel are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Adel
Operator of a medical research firm intended to develop neuropathic treatments and diagnostic systems. The company researches Alzheimer's disease therapeutics by inhibiting tau aggregation and propagation over other antibodies in clinical trials, enabling patients to receive dementia treatment.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2016
- Employees
- 20
- Website
- adelpharm.com/
- Ownership
- Privately Held (backing)
Adel doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Adel shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Adel in its N-PORT filings yet. We sweep new filings monthly.